Pronađeno: 1-7 / 7 radova

Autori: Petzer Andreas L

>> Filter: Samo Article i Review

>> Sve godine

Naslov High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients - final analysis of a randomized, multicenter, phase III trial (Article)
Autori Petzer Andreas L ... Bogdanovic Andrija D  ... (broj koautora 20) 
Info HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, (2012), vol. 97 br. 10, str. 1562-1569
Projekat Novartis
Ispravka Web of Science   Članak   Elečas   Rang časopisa   Citati: Web of Science   Scopus  
facebook sharing button
twitter sharing button
linkedin sharing button
gmail sharing button
copy sharing button
Naslov Pre-treated CML Patients in chronic phase (CP) not achieving at least a major cytogenetic remission (MCyR) after imatinib high dose (HD) induction (800 mg/day, 6 months) are at high risk of progression after dose reduction - Sub-analyses from the CELSG phase III "ISTAHIT" trial (Meeting Abstract)
Autori Petzer Andreas L Fong Dominic Lion Thomas Dyagil Irina Masliak Zvenyslava Bogdanovic Andrija D  Griskevicius Laimonas Lejniece Sandra Goranov Stefan Gercheva Liana Stojanovic Aleksandar Peytchev Dontcho Tzvetkov Nikolay Griniute Rasa Oucheva Radka Grubinger T Kwakkelstein Marthin Rancati Francesca Gastl Guenther A Wolf Dominik 
Info ONKOLOGIE, (2011), vol. 34 br. , Suppl. 6, str. 264-264
Ispravka Web of Science   Elečas   Rang časopisa   Citati: Web of Science  
facebook sharing button
twitter sharing button
linkedin sharing button
gmail sharing button
copy sharing button
Naslov Significantly higher and more rapid cytogenetic and molecular responses can be achieved in pre-treated chronic phase CML patients with high doses of Imatinib as induction therapy (800 mg/day, 6 months) - final results of a Phase III CELSG CML11 "ISTAHIT" TRIAL (Meeting Abstract)
Autori Petzer Andreas L ... Bogdanovic Andrija D  ... (broj koautora 20) 
Info ONKOLOGIE, (2010), vol. 33 br. , Suppl. Suppl. 6, str. 83-83
Ispravka Web of Science   Elečas   Rang časopisa   Citati: Web of Science  
facebook sharing button
twitter sharing button
linkedin sharing button
gmail sharing button
copy sharing button
Naslov High Dose Imatinib Induction (800 Mg/day, 6 Months) Induces Significantly Higher Cytogenetic and Molecular Responses in Pre-treated Chronic Phase CML -phase III Celsg 'istahit' Trial - First Results (Meeting Abstract)
Autori Petzer Andreas L ... Bogdanovic Andrija D  ... Stojanovic Aleksandar ... (broj koautora 20) 
Info HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, (2010), vol. 95 br. , Suppl. Suppl. 2, str. 0133-
Ispravka Web of Science   Elečas   Rang časopisa   Citati: Web of Science  
facebook sharing button
twitter sharing button
linkedin sharing button
gmail sharing button
copy sharing button
Naslov High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study (Article)
Autori Petzer Andreas L Wolf Dominik Fong Dominic Lion Thomas Dyagil Irina Masliak Zvenyslava Bogdanovic Andrija D  Griskevicius Laimonas Lejniece Sandra Goranov Stefan Gercheva Liana Stojanovic Aleksandar Peytchev Dontcho Tzvetkov Nikolay Griniute Rasa Oucheva Radka Ulmer Hanno Kwakkelstein Marthin Rancati Francesca Gastl Guenther A 
Info HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, (2010), vol. 95 br. 6, str. 908-913
Projekat Novartis
Ispravka Web of Science   Članak   Elečas   Rang časopisa   Citati: Web of Science   Scopus  
facebook sharing button
twitter sharing button
linkedin sharing button
gmail sharing button
copy sharing button
Naslov Celsg Cml 11 "Istahit" Phase Iii Study - Planned Interim Analysis: High Doses Of Imatinib Mesylate (800mg/Day) Significantly Improve Rates Of Major And Complete Cytogenetic Remissions (Mcr, Ccr) In Pretreated Ph+/Bcr-Abl(+) Cml Patients In Chronic Phase (Meeting Abstract)
Autori Petzer Andreas L Boskovic Darinka V Gastl Guenther A 
Info BLOOD, (2008), vol. 112 br. 11, str. 406-406
Ispravka Web of Science   Elečas   Rang časopisa   Citati: Web of Science  
facebook sharing button
twitter sharing button
linkedin sharing button
gmail sharing button
copy sharing button
Naslov Multicenter, randomized, phase III study comparing imatinib (Glivec) standard dose (400 mg/d) with imatinib high dose induction (800 mg/d) followed by imatinib maintenance (400 mg/d) in patients with pretreated Ph+/BCR-ABL(+) CML in chronic phase - Results from the first planned interim analysis (CELSG-CML 11 ISTAHIT study) (Meeting Abstract)
Autori Petzer Andreas L Wolf Dominik Fong Dominic Lion Thomas Dyagil Irina Masliak Zvenyslava Boskovic Darinka V Griskevicius Laimonas Lejniece Sandra Spasov Emil Gercheva Liana Stojanovic Aleksandar Peytchev Dontcho Tzvetkov Nikolay Griniute Rasa Stanchev Atanas Kwakkelstein Martin Ulmer Hanno Gastl Guenther A 
Info BLOOD, (2007), vol. 110 br. 11, str. 317A-317A
Ispravka Web of Science   Elečas   Rang časopisa   Citati: Web of Science  
facebook sharing button
twitter sharing button
linkedin sharing button
gmail sharing button
copy sharing button
>> Sve godine

Ispis zapisa u formatu:TXT | BibTeX